NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study focuses on the treatment of cutaneous T-cell lymphoma, with the overall blinded response rate standing at 48% for patients who have completed treatment. “In the Nov. 20, 2025, research report published by Zacks Small-Cap Research, expert analysis indicated strong conviction about the 50-patient enrollment milestone and encouraging clinical results while noting puzzlement at the market’s subdued response. The report maintains Zacks’ $25 per share valuation for Soligenix, based on a probability-adjusted discounted cash flow model that considers potential future revenues from the company’s product pipeline, including HyBryte, SGX302 and SGX945,” reads an article discussing the company.
“Looking ahead, the second quarter 2026 interim analysis represents the next major catalyst for Soligenix. The Zacks report expresses confidence that the trial is trending in the right direction based on the 48% blinded response rate, stating that ‘this update gives us a lot of confidence that the trial is at the very least trending in the right direction.’ With no changes to the financial model following the enrollment milestone, the valuation remains at $25 per share, representing the report’s view that the risk-reward profile remains attractive for investors willing to accept the inherent uncertainties of late-stage clinical development.”
For further information, visit the company’s website at www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study focuses on the treatment of cutaneous T-cell lymphoma, with the overall blinded response rate standing at 48% for patients who have completed treatment. “In the Nov. 20, 2025, research report published by Zacks Small-Cap Research, expert analysis indicated strong conviction about the 50-patient enrollment milestone and encouraging clinical results while noting puzzlement at the market’s subdued response. The report maintains Zacks’ $25 per share valuation for Soligenix, based on a probability-adjusted discounted cash flow model that considers potential future revenues from the company’s product pipeline, including HyBryte, SGX302 and SGX945,” reads an article discussing the company.
“Looking ahead, the second quarter 2026 interim analysis represents the next major catalyst for Soligenix. The Zacks report expresses confidence that the trial is trending in the right direction based on the 48% blinded response rate, stating that ‘this update gives us a lot of confidence that the trial is at the very least trending in the right direction.’ With no changes to the financial model following the enrollment milestone, the valuation remains at $25 per share, representing the report’s view that the risk-reward profile remains attractive for investors willing to accept the inherent uncertainties of late-stage clinical development.”
For further information, visit the company’s website at www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
